James Graf - 06 Dec 2024 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)

Role: Chief Financial Officer
Signature: /s/ James Graf
Issuer symbol: NKGN
Transactions as of: 06 Dec 2024
Net transactions value: $0
Form type: 4
Filing time: 10 Dec 2024, 21:55:54 UTC
Previous filing: 05 Dec 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NKGN	Stock Option (right to buy)	Award	$0	+500,000		$0.000000	500,000	06 Dec 2024	Common Stock	500,000	$0.4380	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 25% vesting immediately as of the grant date, and the remaining options vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Content

On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 25% vesting immediately as of the grant date, and the remaining options vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.